Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease. The Polish biotech tested two daily doses of the drug, dubbed CPL’36, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback